Eli Lilly & Co $64.31

up +0.59


23/7/2014 01:58 PM  |  NYSE : LLY  
Industries : Drugs / Drug Manufacturers - Major
Get Trend Analysis Icon Get LLY Trend Analysis - it has outperformed the S&P 500 by 9%

Partner Headlines

  1. New Study Shows Beta-Amyloid Imaging Is Associated With Altered Diagnosis ...

    Benzinga
  2. Lilly And Immunocore Enter Immunotherapy Agreement To Co-Discover And Co-Develop ...

    Benzinga
  3. Benzinga's Top #PreMarket Gainers

    Benzinga
  4. US Stock Futures Mostly Higher Ahead Of Goldman Sachs Earnings

    Benzinga
  5. Barclays Downgrades Pharmaceutical Sector

    Benzinga
  6. UPDATE: Barclays Upgrades Eli Lilly Despite Sector Downgrade

    Benzinga
  7. Benzinga's Top Upgrades

    Benzinga
  8. Eli Lilly is on the Right Track

    GuruFocus
  9. Celgene Sees Better Results For Psoriatic Arthritis

    IBD
  10. Eli Lilly Bets Big on Diabetes, Cancer Drugs

    FoxBusiness
  11. Novo Nordisk Raises Insulin Prices As Demand Grows

    IBD
  12. ASCO Meeting Day 3: Do More Treatments Equal A Longer Life?

    Benzinga
  13. ASCO Meeting Day 2: 'Promising' Results From JNJ's Imbruvica & Targeted ...

    Benzinga
  14. John Paulson's 4 Stocks Trading for Less Than He Paid for Them

    GuruFocus
  15. Lilly Says Abemaciclib in Phase 1 Study Demonstrated Single-Agent Activity

    Benzinga
  16. Eli Lilly insulin trial succeeds

    IBD
  17. Cross-Border Megamergers Drive Global Takeover Boom

    IBD
  18. Google Celebrates Dorothy Hodgkin & Her Contributions To Chemistry

    Benzinga
  19. Eli Lilly's Basal Insulin Outperforms Lantus In Trial

    IBD
  20. UPDATE: Eli Lilly Announces Peglispro Shows Superiority Compared to Insulin ...

    Benzinga
  21. Can Pfizer Make Up Its Loss?

    GuruFocus
  22. Merck Sells Consumer Unit To Bayer To Focus On R&D

    IBD
  23. Bayer Buys Merck Consumer Care Unit

    FoxBusiness
  24. Will Pfizer's Q1 2014 Earnings Beat the Street on May 5, 2014?

    GuruFocus
  25. AstraZeneca Rejects Pfizer's $106B Buyout Bid

    FoxBusiness
  26. Novo Nordisk Struggles In U.S. Market; Q1 Sales Miss

    IBD
  27. Novo Nordisk Q1 Revenue Misses; Guidance Lowered

    IBD
  28. Vanguard Health Care Fund's Top Quarterly Holdings

    GuruFocus
  29. Actavis Earns Over-The-Top Q1

    IBD
  30. Actavis Beats Q1 Views, Looks To Supersized Future

    IBD
  31. Actavis Q1 Earnings Beat On Generic Cymbalta Surprise

    IBD
  32. China Rule Change Further Opens Yuan To World Markets

    IBD
  33. These Three Pharmaceutical Companies Shake The Market With Their Deal

    GuruFocus
  34. Drugmakers' Q1 was anemic

    IBD
  35. Eli Lilly Jr. Made His Firm A Pharmaceutical Power

    IBD
  36. Earnings Scheduled For April 24, 2014

    Benzinga
  37. Big Pharmas Swap Specialties

    IBD
  38. Drugmakers Prod European Stocks To Post-Easter Rally

    IBD
  39. Benzinga's M&A Chatter for Tuesday April 22, 2014

    Benzinga
  40. Novartis, Glaxo Swap Units; Valeant Bids For Allergan

    IBD
  41. Stocks Rise In Higher Volume; Gilead Up After Hours

    IBD
  42. Pharma Deal Frenzy: A Bid to Boost Profits, Cut Risk

    FoxBusiness
  43. Amgen Slumps After 1Q Earnings Miss

    FoxBusiness
  44. Novartis, Glaxo Swap Units; Lilly Buying Animal Biz

    IBD
  45. Stock Futures Mixed And Busy; Allergan, Netflix, Glaxo Climb

    IBD
  46. Novartis Announces Multi-Billion-Dollar Revamp

    FoxBusiness
  47. US Stock Futures Edge Higher Ahead Of McDonald's Earnings

    Benzinga
  48. Stock Futures Steady Amid Raft of Health M&A

    FoxBusiness
  49. Wall Street Ticks Up as Traders Parse News Deluge

    FoxBusiness
  50. ELI LILLY

    IBD
Trading Center